Fresenius strengthens its Management Board team – New appointment at Fresenius Kabi – Expansion of Human Resources/Legal to include ESG

• Pierluigi Antonelli takes over as Chairman of the Management Board of Fresenius Kabi
• Sebastian Biedenkopf to leave the company at the end of his contract
• Michael Moser to assume responsibility for Human Resources, Risk Management, Legal as well as Environmental, Social and Governance (ESG) by 1 August 2023 at the latest

The healthcare group Fresenius strengthens its Management Board team. The Supervisory Board of Fresenius Management SE has appointed Pierluigi Antonelli (56) as Chief Executive Officer of Fresenius Kabi with effect from 1 March 2023. He succeeds Michael Sen, who had held this position on an interim basis after being appointed Chairman of the Management Board of Fresenius on 1 October 2022. The current scope of the Human Resources, Risk Management and Legal departments will be broadened to also cover Environmental, Social and Governance (ESG) going forward. Sebastian Biedenkopf (58) will leave the company by mutual agreement once his contract expires at the end of the year. He will support his successor Michael Moser (46), who will join Fresenius on 1 August 2023 at the latest, until the end of his contract to ensure a seamless handover.

“With Pierluigi Antonelli and Michael Moser, two internationally experienced top managers are joining our company. I am very pleased that they are joining the team and taking over responsibility as we are shaping #FutureFresenius in the coming years,” said Wolfgang Kirsch, Chairman of the Supervisory Board of Fresenius. “I would like to thank Sebastian Biedenkopf for his great commitment over the past years. In his role, he has made strong contributions to maintain Fresenius’ stability during challenging times. We wish him all the best in his future endeavours, both professionally and personally.”

Pierluigi Antonelli joins Fresenius with extensive operational expertise in the pharmaceutical industry with a focus on product development and launches across key international markets, business development and strategy crafting as well as implementation. In his previous role since 2019, he was the CEO of Angelini Pharma, a subsidiary of the Italian Angelini Group specializing in brain health and consumer health. Prior to that, he held senior leadership positions at Novartis Oncology, Sandoz, Merck & Co. and Bristol Myers Squibb in the United States and across Europe, and beyond.

Michael Moser served as deputy CEO and CFO at Enerjisa, the leading energy company in Turkey, since 2019. Previously, since 2008, he held various leadership positions at energy provider E.ON, one of the major investors in Energjisa. During his time at E.ON, Moser was, among other things, a board member with responsibility for legal, compliance, M&A and portfolio optimization at the listed company Eneva in Brazil and later also responsible for the spin-off and IPO of the German energy company Uniper. With a degree in law and business administration, he started his career at Baker & McKenzie with a focus on M&A and corporate law. In recent years, he has worked in various countries including the United States, China, Brazil, France, the United Kingdom and Switzerland.

“The trajectory of Fresenius Kabi has been set with ‘Vision 2026’ towards profitable growth,” said Fresenius CEO Michael Sen. “Thanks to his many years of experience in the pharmaceutical sector, Pierluigi Antonelli has the expertise to further support Fresenius Kabi on this journey. Michael Moser is not only a proven expert in the areas of compliance and risk management, but also brings extensive experience in portfolio management and navigating periods of transformation as well as in the energy industry managing sustainability issues.”

“I would like to thank the Supervisory Board of Fresenius Management SE for the trust they have placed in me,” said Pierluigi Antonelli. “Fresenius Kabi operates at the heart of Fresenius with a clear direction laid out with ‘Vision 2026’, which we will further shape together. I can hardly imagine a more exciting opportunity than leading this company into the future. Fresenius Kabi is already a market leader across multiple markets, offering healthcare products and solutions for chronically ill patients and competing in dynamic growth areas with biosimilars and MedTech. I will focus on working with the team to further strengthen the company’s position and drive profitable growth across the focus segments.”

“Fresenius is a great company, which, with its employees around the world, will decisively shape the future of medical technology and health,” said Michael Moser. “What always fascinates and motivates me, across all my professional activities, is people. Fresenius cares about people’s health in a special way. I am very much looking forward to contributing to Fresenius’ journey with my experience in change and growth processes, and in working together with the entire workforce to drive transformation processes.”

This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, the availability of financing and unforeseen impacts of international conflicts.
Fresenius does not undertake any responsibility to update the forward-looking statements in this release.